Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Post-Mkt 04-16 17:29:01 EDT

3.98

+0.05

+1.27%

盘后3.99

+0.01+0.25%

17:17 EDT

High4.04	Low3.85	Vol1.11M
Open4.03	D1 Closing3.93	Amplitude4.71%
Mkt Cap479.97M	Tradable Cap463.78M	Total Shares120.60M
T/O4.36M	T/O Rate0.95%	Tradable Shares116.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":3.98,"timestamp":1776369600000,"preClose":3.93,"halted":0,"volume":1107701,"hourTrading":{"tag":"盘后","latestPrice":3.99,"preClose":3.98,"latestTime":"17:17 EDT","volume":4184,"amount":16649.9987168,"timestamp":1776374276638,"change":0.01,"changeRate":0.002513,"amplitude":0.01005},"delay":0,"changeRate":0.012722646310432524,"floatShares":116528006,"shares":120595200,"eps":-0.53,"marketStatus":"Post-Mkt","change":0.05,"latestTime":"04-16 17:29:01 EDT","open":4.03,"high":4.035,"low":3.85,"amount":4364240.3638183,"amplitude":0.047074,"askPrice":4.2,"askSize":350,"bidPrice":3.8,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-0.53,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776384000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":3.93,"preHourTrading":{"tag":"盘前","latestPrice":4.15,"preClose":3.93,"latestTime":"09:24 EDT","volume":4641,"amount":19086.943239,"timestamp":1776345846523,"change":0.22,"changeRate":0.05598,"amplitude":0.061069},"postHourTrading":{"tag":"盘后","latestPrice":3.99,"preClose":3.98,"latestTime":"17:17 EDT","volume":4184,"amount":16649.9987168,"timestamp":1776374276638,"change":0.01,"changeRate":0.002513,"amplitude":0.01005},"volumeRatio":0.818151,"impliedVol":1.1825,"impliedVolPercentile":0.444},"requestUrl":"/m/hq/s/ACRS/wiki","defaultTab":"wiki","newsList":[{"id":"2628217055","title":"Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2628217055","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628217055?lang=en_us&edition=fundamental","pubTime":"2026-04-17 00:37","pubTimestamp":1776357469,"startTime":"0","endTime":"0","summary":"In a report released today, Adam Vogel from Craig-Hallum maintained a Buy rating on Aclaris Therapeutics, with a price target of $10.00. Vogel cove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aclaris-therapeutics-acrs-gets-a-buy-from-craig-hallum-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aclaris-therapeutics-acrs-gets-a-buy-from-craig-hallum-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627187252","title":"Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2627187252","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627187252?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:34","pubTimestamp":1776342844,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $8.94, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627187352","title":"Aclaris Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2627187352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627187352?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:33","pubTimestamp":1776342807,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Z0R2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627409218","title":"Aclaris Therapeutics Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627409218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627409218?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:29","pubTimestamp":1776342540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2026 08:29 ET (12:29 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627626707","title":"U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2627626707","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627626707?lang=en_us&edition=fundamental","pubTime":"2026-04-16 15:55","pubTimestamp":1776326124,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial ServicesApril 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nL4N40Z0OT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DLLL","AMT","GLW","KMX","AWK","CZR","ALLO","AMD","APH","BBIO","AMDU","ANET","CME","OBDC","CALX","CSCS","USJW.SI","AMDY","CLH","AMDG","BXMT","CENX","COF","CE","BFH","AEP","COTG","DOGD","CHDN","BAC","DELL","GOOG","COST","CSCO","BYD","DAMD","ALNY","ARCB","AXPG","AXP","AESI","CIEN","DDOG","ACRS","AXON","BP","CRUS","DHI","BPH","FIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626130851","title":"Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2626130851","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626130851?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:01","pubTimestamp":1775764897,"startTime":"0","endTime":"0","summary":"Cardiff Oncology named board member Mani Mohindru as president and CEO, following her stint as interim CEO.Josh Muntner was appointed CFO effective April 6; he previously served as CFO of Imvax and Mesoblast.Ajay Aggarwal was named COO effective April 27; he most recently served as SVP and head of clinical development at Aclaris Therapeutics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL6mHz76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4588","CRDF","BK7501","IE00BN0W2T93.GBP","BK4585","MSB.AU","LU2210149790.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","BK4007","IE00BN0W2W23.USD","BK7067","LU2095319765.USD","BK7508","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","NDAQ","SG9999014021.USD","IE00BKPKM429.USD","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625949443","title":"Aclaris CEO to join fireside chat at H.C. Wainwright skin disease conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2625949443","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625949443?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:31","pubTimestamp":1775651462,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics will join H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026.Management will take part in a fireside chat at 12:00 PM EDT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1lG5RP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4007","SG9999014021.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4112","BK4588","ACRS","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014005.SGD","NDAQ","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623805555","title":"Aclaris Therapeutics Price Target Maintained With a $8.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2623805555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623805555?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:11","pubTimestamp":1774966260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 10:11 ET (14:11 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622820371","title":"Aclaris Therapeutics Phase 2a week 12 EASI improvement climbs 77% on ATI-2138 10 mg BID; BSA improvement grows 70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622820371","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622820371?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:10","pubTimestamp":1774620650,"startTime":"0","endTime":"0","summary":"Aclaris reported additional Phase 2a results that were presented in an electronic poster at the 2026 American Academy of Dermatology Annual Meeting for ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, in moderate-to-severe atopic dermatitis.At week 12, the 10 mg BID dose cohort showed a 77% improvement in EASI and a 70% improvement in affected body surface area.Week 12 outcomes also included a 50% improvement in peak pruritus numerical rating scale and a 65% improvement in Dermatology Life Quality Index.The company said near-complete ITK target occupancy was observed across the dosing interval and tape-strip analyses indicated modulation of multiple immune pathway markers.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL7y1QdH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","SG9999014021.USD","BK4588","IE00BKPKM429.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","ACRS","LU2210149790.SGD","BK4112","IE00BN0W2V16.EUR","BK4585","SG9999014013.SGD","LU0314104364.USD","SG9999014039.USD","BK4007","IE00BN0W2T93.GBP","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622820127","title":"Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138","url":"https://stock-news.laohu8.com/highlight/detail?id=2622820127","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622820127?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:10","pubTimestamp":1774620600,"startTime":"0","endTime":"0","summary":"- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March  27, 2026 (GLOBE NE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3263826/37216/en/Results-Presented-at-2026-American-Academy-of-Dermatology-AAD-Annual-Meeting-Provide-Additional-Support-for-the-Therapeutic-Potential-of-ATI-2138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EASI","ATI","AFG","BK4117","BK4007","AD","BK4006","IE00B19Z4B17.USD","BK4187","ACRS","IE00B66KJ199.SGD","IE0031619046.USD","BK4107","LU2065731478.USD","IE00B7SZL793.SGD","LU1878469433.USD","BSA","LU0963586101.USD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620737928","title":"Aclaris Therapeutics to present Phase 2a ATI-2138 atopic dermatitis trial results at 2026 AAD meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620737928","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620737928?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:00","pubTimestamp":1774018837,"startTime":"0","endTime":"0","summary":"An ePoster will present results from an open-label Phase 2a trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, in patients with moderate-to-severe atopic dermatitis.The presentation is scheduled for the 2026 American Academy of Dermatology Annual Meeting and will include results not previously reported from the Phase 2a trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL2NRRs3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B64PRP62.GBP","BK4112","BK4585","BK4007","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","IE00BGHQF748.EUR","ACRS","LU2095319765.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620402602","title":"Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620402602","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620402602?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:22","pubTimestamp":1773922920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 08:22 ET (12:22 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232059","title":"Aclaris Therapeutics completes enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232059","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232059?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831315,"startTime":"0","endTime":"0","summary":"Aclaris reported completion of patient enrollment in a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug  in moderate-to-severe atopic dermatitis. The study includes 109 patients and will evaluate efficacy and safety through week 24. The primary endpoint is percent change from baseline in Eczema Area and Severity Index  at week 24. Secondary endpoints at week 24 include EASI-50, EASI-75 and EASI-90 responses, plus validated Investigator Global Assessment response. Top-line results have not yet been presented and are expected in the fourth quarter of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbZFDl8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4112","LU2095319765.USD","BK4588","BK4585","LU2210150020.SGD","BK4007","IE00BGHQF748.EUR","SG9999014005.SGD","ACRS","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620320812","title":"Aclaris Therapeutics Inc - Top Line Results From Phase 2 Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620320812","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620320812?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUA90RNXD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620595255","title":"Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620595255","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620595255?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831300,"startTime":"0","endTime":"0","summary":"- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March  18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focuse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258004/37216/en/Aclaris-Therapeutics-Completes-Enrollment-in-Phase-2-Trial-of-Bosakitug-ATI-045-in-Atopic-Dermatitis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1878469433.USD","TSLP","LU1169589451.USD","BK4132","BSA","PK","IGA","ATI","AD","BK4023","LU2065731478.USD","BK4181","LU0963586101.USD","IE00B19Z4B17.USD","EASI","LU1169590202.USD","BK4006","ACRS","IE0031619046.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4007","BK4187","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618908456","title":"Aclaris Therapeutics Raises $20 Million in Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618908456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618908456?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:13","pubTimestamp":1773277990,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics ( ($ACRS) ) has issued an announcement. On March 10, 2026, Aclaris Therapeutics, Inc. raised $20 million in gross proceeds thr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aclaris-therapeutics-raises-20-million-in-equity-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aclaris-therapeutics-raises-20-million-in-equity-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4215","BK4007","ACRS","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618768479","title":"Aclaris Therapeutics sells 5.7 million shares for USD 20 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618768479","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618768479?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:52","pubTimestamp":1773262374,"startTime":"0","endTime":"0","summary":"Aclaris sold 5.7 million shares of common stock for aggregate gross proceeds of USD 20 million under its amended and restated sales agreement with Leerink Partners and Cantor Fitzgerald. The shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbrpkP9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007","BK4207","MNSH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616342225","title":"Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342225","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342225?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539200,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., March  03, 2026   -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday March 10, 2026, at 1:40 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Leerink Partners 2026 Global Healthcare Conference in Miami, FL. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcasts will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/03/3248195/37216/en/Aclaris-Therapeutics-to-Participate-in-the-Leerink-Partners-2026-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","ACRS","XBI","LU0128526141.USD","BK4007","BK4581","BK4137","BK4588","BK4585","LABU","LU0029874061.USD","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614832984","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2614832984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614832984?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:00","pubTimestamp":1772190000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Arbor Realty Tr                                  4Q       .13   8:30 AM. ·Delek US Hldgs                                    4Q      (.19)  7:00 AM. ·NW Natural Hldg                                  4Q      1.36   6:00 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRK.A","BEEP","CLMT","AZO","ACHR","ADT","AMRX","ARCT","BTSG","CORZ","LIF","CRD.A","ALXO","ASAN","CGEN","CERS","BLTE","AMLX","ACRS","ACEL","BRCB","AMWD","BOX","CMPX","CRC","ATRA","ANTA","ABR","GSAT","AAON","CRCT","CVEO","AMRC","CRI","ANIP","BBY","NPCE","ASTH","ALG","BCYC","CXDO","AMR","CRD.B","BGS","STNE","BRK.B"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614237030","title":"Craig-Hallum Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614237030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614237030?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:56","pubTimestamp":1772117779,"startTime":"0","endTime":"0","summary":"In a report released today, Adam Vogel from Craig-Hallum reiterated a Buy rating on Aclaris Therapeutics, with a price target of $10.00. Vogel cove...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":-0.0051},{"period":"1month","weight":0.0508},{"period":"3month","weight":0.4719},{"period":"6month","weight":1.0684},{"period":"1year","weight":2.5089},{"period":"ytd","weight":0.3056}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.145543},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.038718},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.021975},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.004793},{"month":5,"riseRate":0.5,"avgChangeRate":-0.043272},{"month":6,"riseRate":0.6,"avgChangeRate":-0.004956},{"month":7,"riseRate":0.6,"avgChangeRate":0.009999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019617},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}